The first biosimilar for TNF inhibitors (infliximab) was approved in Europe in 2013, and soon after, biosimilars gradually replaced original TNF inhibitors, thus reducing the costs of medical treatment with TNF inhibitors.13 Concomitantly, newer biologics such as vedolizumab14 and ustekinumab15 were introduced as treatments for IBD, followed by new treatment strategies such as janus-kinases inhibitors (tofacitinib).16 With the development of IBD therapies, the use of corticosteroids has declined, but the extent varies between countries.17, , , , –22. Here, TNF is linked to inflammatory bowel disease.